{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:21:57Z","timestamp":1784154117649,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40266-025-01272-8","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:04:31Z","timestamp":1773770671000},"page":"313-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of DOACs in Patients with Atrial Fibrillation and History of Falls or Risk of Falls: The Liverpool AF-Falls Project. A Systematic Review and Bayesian Network Meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-249X","authenticated-orcid":false,"given":"Thibaut","family":"Galvain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2801-0505","authenticated-orcid":false,"given":"Ruaraidh","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-2290","authenticated-orcid":false,"given":"Sarah","family":"Donegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-6445","authenticated-orcid":false,"given":"Robert","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1157-2093","authenticated-orcid":false,"given":"Gabriela","family":"Czanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"1272_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1747493019897870","volume":"16","author":"G Lippi","year":"2021","unstructured":"Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16:217\u201321.","journal-title":"Int J Stroke"},{"key":"1272_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983\u20138.","journal-title":"Stroke"},{"key":"1272_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857\u201367.","journal-title":"Ann Intern Med"},{"key":"1272_CR4","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955\u201362.","journal-title":"Lancet"},{"key":"1272_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jacc.2023.05.032","volume":"82","author":"W Deng","year":"2023","unstructured":"Deng W, Mansour M, Song B, Hou H, Liu K, Xu Y, et al. Fall outcomes with left atrial appendage occlusion vs direct oral anticoagulants for atrial fibrillation. J Am Coll Cardiol. 2023;82:379\u201381.","journal-title":"J Am Coll Cardiol"},{"key":"1272_CR6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1055\/s-0042-1750385","volume":"122","author":"DA Gorog","year":"2022","unstructured":"Gorog DA, Gue YX, Chao T-F, Fauchier L, Ferreiro JL, Huber K, et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific expert consensus paper. Thromb Haemost. 2022;122:1625\u201352.","journal-title":"Thromb Haemost"},{"key":"1272_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/jgs.13200","volume":"63","author":"O Bahri","year":"2015","unstructured":"Bahri O, Roca F, Lechani T, Druesne L, Jouanny P, Serot J-M, et al. Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J Am Geriatr Soc. 2015;63:71\u20136.","journal-title":"J Am Geriatr Soc"},{"key":"1272_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1055\/s-0043-1769735","volume":"124","author":"M Grymonprez","year":"2024","unstructured":"Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb Haemost. 2024;124:135\u201348.","journal-title":"Thromb Haemost"},{"key":"1272_CR9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1770724","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Li S, Liu X, Lip GYH, Guo L, Zhu W. Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis. Thromb Haemost. 2023. https:\/\/doi.org\/10.1055\/s-0043-1770724.","journal-title":"Thromb Haemost"},{"key":"1272_CR10","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1055\/s-0042-1756355","volume":"122","author":"GF Romiti","year":"2022","unstructured":"Romiti GF, Proietti M, Bonini N, Ding WY, Boriani G, Huisman MV, et al. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III. Thromb Haemost. 2022;122:2030\u201341.","journal-title":"Thromb Haemost"},{"key":"1272_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archinte.159.7.677","volume":"159","author":"M Man-Son-Hing","year":"1999","unstructured":"Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677\u201385.","journal-title":"Arch Intern Med"},{"key":"1272_CR12","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.amjmed.2005.02.022","volume":"118","author":"BF Gage","year":"2005","unstructured":"Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118:612\u20137.","journal-title":"Am J Med"},{"key":"1272_CR13","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40264-022-01231-x","volume":"45","author":"T Galvain","year":"2022","unstructured":"Galvain T, Hill R, Donegan S, Lisboa P, Lip GYH, Czanner G. Efficacy and safety of anticoagulants in patients with atrial fibrillation and history of falls or risk of falls: a systematic review and multilevel meta-analysis. Drug Saf. 2022;45:1349\u201362.","journal-title":"Drug Saf"},{"key":"1272_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373\u2013498.","journal-title":"Eur Heart J"},{"key":"1272_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1-156.","journal-title":"Circulation"},{"key":"1272_CR16","doi-asserted-by":"publisher","unstructured":"Dentali F, Riva N, Crowther M, Turpie AGG, Lip GYH, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.115410","DOI":"10.1161\/CIRCULATIONAHA.112.115410"},{"key":"1272_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijcard.2015.11.084","volume":"204","author":"GYH Lip","year":"2016","unstructured":"Lip GYH, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, et al. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol. 2016;204:88\u201394.","journal-title":"Int J Cardiol"},{"key":"1272_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5058","volume":"359","author":"JA L\u00f3pez-L\u00f3pez","year":"2017","unstructured":"L\u00f3pez-L\u00f3pez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058.","journal-title":"BMJ"},{"key":"1272_CR19","doi-asserted-by":"crossref","unstructured":"Deng K, Cheng J, Rao S, Xu H, Li L, Gao Y. Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis. Front Med [Internet]. 2020 [cited 2023 Mar 3];7. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.00107.","DOI":"10.3389\/fmed.2020.00107"},{"key":"1272_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/s-0041-1739411","volume":"122","author":"T-F Chao","year":"2022","unstructured":"Chao T-F, Joung B, Takahashi Y, Lim TW, Choi E-K, Chan Y-H, et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost. 2022;122:20\u201347.","journal-title":"Thromb Haemost"},{"key":"1272_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13643-022-01937-0","volume":"11","author":"T Galvain","year":"2022","unstructured":"Galvain T, Hill R, Donegan S, Lisboa P, Lip GYH, Czanner G. The management of anticoagulants in patients with atrial fibrillation and history of falls or risk of falls: protocol for a systematic review and meta-analysis. Syst Rev. 2022;11:63.","journal-title":"Syst Rev"},{"key":"1272_CR22","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021) [Internet]. Cochrane, 2021; Available from: www.training.cochrane.org\/handbook."},{"key":"1272_CR23","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:n71.","journal-title":"BMJ"},{"key":"1272_CR24","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jacc.2016.06.034","volume":"68","author":"J Steffel","year":"2016","unstructured":"Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF\u2013TIMI 48 analysis. J Am Coll Cardiol. 2016;68:1169\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"1272_CR25","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, The Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients: definitions of major bleeding in clinical studies. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"key":"1272_CR26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1272_CR27","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105\u201324.","journal-title":"Stat Med"},{"key":"1272_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1198\/016214505000001302","volume":"101","author":"G Lu","year":"2006","unstructured":"Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc. 2006;101:447\u201359.","journal-title":"J Am Stat Assoc"},{"key":"1272_CR29","unstructured":"van Valkenhoef G, Kuiper J. gemtc: network meta-analysis using Bayesian methods. R package version 0.6-1 2014. [Internet]. Available from: https:\/\/cran.r-project.org\/web\/packages\/gemtc\/gemtc.pdf."},{"key":"1272_CR30","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","volume":"7","author":"SP Brooks","year":"1998","unstructured":"Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7:434\u201355.","journal-title":"J Comput Graph Stat"},{"key":"1272_CR31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jrsm.1085","volume":"4","author":"S Donegan","year":"2013","unstructured":"Donegan S, Williamson P, D\u2019Alessandro U, Tudur Smith C. Assessing key assumptions of network meta-analysis: a review of methods: assessing assumptions of network meta-analysis. Res Synth Methods. 2013;4:291\u2013323.","journal-title":"Res Synth Methods"},{"key":"1272_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jrsm.57","volume":"3","author":"A Chaimani","year":"2012","unstructured":"Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods. 2012;3:161\u201376.","journal-title":"Res Synth Methods"},{"key":"1272_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s11239-019-01898-7","volume":"48","author":"B Miao","year":"2019","unstructured":"Miao B, Alberts MJ, Bunz TJ, Coleman CI. Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls. J Thromb Thrombolysis. 2019;48:366\u201372.","journal-title":"J Thromb Thrombolysis"},{"key":"1272_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.amjmed.2017.10.036","volume":"131","author":"MP Rao","year":"2018","unstructured":"Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, et al. Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial. Am J Med. 2018;131:269-275.e2.","journal-title":"Am J Med"},{"key":"1272_CR35","doi-asserted-by":"crossref","unstructured":"Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016:i2868.","DOI":"10.1136\/bmj.i2868"},{"key":"1272_CR36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3233\/JAD-180219","volume":"65","author":"L Fanning","year":"2018","unstructured":"Fanning L, Ryan-Atwood TE, Bell JS, Meretoja A, McNamara KP, Darzins P, et al. Prevalence, safety, and effectiveness of oral anticoagulant use in people with and without dementia or cognitive impairment: a systematic review and meta-analysis. J Alzheimers Dis. 2018;65:489\u2013517.","journal-title":"J Alzheimers Dis"},{"key":"1272_CR37","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1161\/STROKEAHA.121.036757","volume":"53","author":"D Kim","year":"2022","unstructured":"Kim D, Yang PS, Sung JH, Jang E, Yu HT, Kim TH, et al. Effectiveness and safety of anticoagulation therapy in frail patients with atrial fibrillation. Stroke. 2022;53:1873\u201382.","journal-title":"Stroke"},{"key":"1272_CR38","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.115.018544","volume":"133","author":"JP Piccini","year":"2016","unstructured":"Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133:352\u201360.","journal-title":"Circulation"},{"key":"1272_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/joim.13140","volume":"289","author":"GYH Lip","year":"2021","unstructured":"Lip GYH, Keshishian AV, Kang AL, Dhamane AD, Luo X, Li X, et al. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. J Intern Med. 2021;289:42\u201352.","journal-title":"J Intern Med"},{"key":"1272_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008643","volume":"7","author":"BK Martinez","year":"2018","unstructured":"Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. JAHA. 2018;7:e008643.","journal-title":"JAHA"},{"key":"1272_CR41","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1161\/STROKEAHA.122.041628","volume":"54","author":"D Caldeira","year":"2023","unstructured":"Caldeira D, da Alves Silva P, Pinto FJ. Clinical outcomes of anticoagulated patients with atrial fibrillation after falls or head injury: insights from RE-LY. Stroke. 2023;54:1656\u20139.","journal-title":"Stroke"},{"key":"1272_CR42","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med"},{"key":"1272_CR43","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med"},{"key":"1272_CR44","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"1272_CR45","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"1272_CR46","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1161\/CIRCOUTCOMES.112.965988","volume":"5","author":"S Schneeweiss","year":"2012","unstructured":"Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5:480\u20136.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1272_CR47","first-page":"93","volume":"8","author":"A Tawfik","year":"2016","unstructured":"Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS, Boon H, et al. Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Clin Pharmacol. 2016;8:93\u2013107.","journal-title":"Clin Pharmacol"},{"key":"1272_CR48","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/jth.14131","volume":"16","author":"Z Wolfe","year":"2018","unstructured":"Wolfe Z, Khan SU, Nasir F, Raghu Subramanian C, Lash B. A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants. J Thromb Haemost. 2018;16:1296\u2013306.","journal-title":"J Thromb Haemost"},{"key":"1272_CR49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/14017431.2019.1594353","volume":"53","author":"C Antza","year":"2019","unstructured":"Antza C, Doundoulakis I, Akrivos E, Economou F, Vazakidis P, Haidich A-B, et al. Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis. Scand Cardiovasc J. 2019;53:48\u201354.","journal-title":"Scand Cardiovasc J"},{"key":"1272_CR50","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","volume":"115","author":"EM Hylek","year":"2007","unstructured":"Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689\u201396.","journal-title":"Circulation"},{"key":"1272_CR51","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1161\/01.STR.26.8.1471","volume":"26","author":"RG Hart","year":"1995","unstructured":"Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995;26:1471\u20137.","journal-title":"Stroke"},{"key":"1272_CR52","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/0272989X13487604","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence synthesis for decision making 1: introduction. Med Decis Mak. 2013;33:597\u2013606.","journal-title":"Med Decis Mak"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01272-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01272-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01272-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:04:14Z","timestamp":1774969454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01272-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1272"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01272-8","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RH declares a financial\u2014non-personal, non-specific interest, having delivered educational workshops on health economics, medicines management and HTA for cancer specialists supported by unrestricted sponsorship by the pharmaceutical industry and an industry association (March 2019). No fees were received personally. Not specific to the topic of the review. GYHL: Consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-PI of the AFFIRMO project on multimorbidity in AF (grant agreement No 899871), TARGET project on digital twins for personalized management of atrial fibrillation and stroke (grant agreement No 101136244) and ARISTOTELES project on artificial intelligence for management of chronic long term conditions (grant agreement No 101080189), which are all funded by the EU\u2019s Horizon Europe Research & Innovation programme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Codes will be available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Template data collection form, data extracted, analytical code and any other study documents will be available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Conceptualization: GYHL, RW, GC, SD, RH and TG; methodology: GYHL, RW, GC, SD, RH and TG; formal analysis: GC and TG; investigation: GYHL, RW, GC, SD, RH and TG; data curation: GC and TG; writing\u2014original draft: TG; writing\u2014review and editing: GYHL, RW, GC, SD, RH and TG; visualization: TG; final approval: GYHL, RW, GC, SD, RH and TG.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}